New phase 3 trial – baxdrostat, a selective aldosterone synthase inhibitor, significantly reduced 24 h ambulatory systolic blood pressure vs placebo in patients with resistant hypertension, study suggests.
Read more: spkl.io/6010AxFRe
Thread
Nenhum Voo ainda